Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis.

Abstract:

OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic review and random effects meta-analysis of all available randomized controlled trials (RCTs) evaluating the safety and efficacy of PTAS (in comparison with medical therapy) for sICAS. RESULTS:Three RCTs (678 total patients) were included in the quantitative analysis. PTAS was associated with a higher risk of recurrent ischemic stroke in the territory of qualifying artery both within 30 days [risk ratio (RR) = 2.21, 95% confidence interval (CI) 1.10-4.43] and 1 year (RR = 1.92, 95% CI 1.10-3.36). PTAS was also related to a higher risk of any ischemic stroke within 30 days from the index event (RR = 2.08, 95% CI 1.17-3.71). The risk for intracranial hemorrhage was found to be higher in PTAS patients both within 30 days (RR = 10.60, 95% CI 1.98-56.62) and 1 year (RR = 8.15, 95% CI 1.50-44.34). The composite outcome of any stroke or death within 1 year (RR = 2.29, 95% CI 1.13-4.66) and 2 years (RR = 1.52, 95% CI 1.04-2.21) was higher in PTAS than in medical therapy. PTAS was associated with a higher risk of any stroke or death within 2 years in the sICAS subgroup located in posterior circulation (RR = 2.37, 95% CI 1.27-4.42). CONCLUSIONS:PTAS is associated with adverse early and long-term outcomes and should not be recommended in patients with sICAS. Further research to identify subgroups of patients who could also serve as candidates for future interventional trials along with efforts to reduce procedure-related complications are needed.

journal_name

Ther Adv Neurol Disord

authors

Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

doi

10.1177/1756285616650357

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

351-8

issue

5

eissn

1756-2856

issn

1756-2864

pii

10.1177_1756285616650357

journal_volume

9

pub_type

杂志文章
  • HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.

    abstract:Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420951087

    authors: Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

    更新日期:2020-10-07 00:00:00

  • Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.

    abstract::Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials a...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285616628766

    authors: Khatri BO

    更新日期:2016-03-01 00:00:00

  • Botulinum toxin in the management of blepharospasm: current evidence and recent developments.

    abstract::Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285614557475

    authors: Hellman A,Torres-Russotto D

    更新日期:2015-03-01 00:00:00

  • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

    abstract:OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285614563056

    authors: Hadden RD,Marreno F

    更新日期:2015-01-01 00:00:00

  • Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

    abstract::Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418803248

    authors: Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

    更新日期:2018-10-05 00:00:00

  • Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.

    abstract:Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419887596

    authors: Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

    更新日期:2019-12-02 00:00:00

  • Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.

    abstract::The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285616640684

    authors: Tallner A,Pfeifer K,Mäurer M

    更新日期:2016-07-01 00:00:00

  • Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.

    abstract::The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285614549554

    authors: Freedman MS

    更新日期:2014-11-01 00:00:00

  • Wernicke-Korsakoff syndrome associated with mtDNA disease.

    abstract:Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420938972

    authors: Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

    更新日期:2020-07-30 00:00:00

  • Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.

    abstract::Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily, oral immunomodulatory therapy, has demonstrated efficacy across...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285617722500

    authors: Miller AE

    更新日期:2017-12-01 00:00:00

  • C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

    abstract:Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286420935697

    authors: Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

    更新日期:2020-08-10 00:00:00

  • An update on the treatment of Sydenham's chorea: the evidence for established and evolving interventions.

    abstract::Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285610382063

    authors: Walker KG,Wilmshurst JM

    更新日期:2010-09-01 00:00:00

  • Treatment of neuromyelitis optica: current debate.

    abstract::Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that largely affects optic nerves and spinal cord. Recent studies have identified an elevation of serum anti-aquaporin 4 antibody as a hallmark of NMO. Typical cases of NMO significantly differ from multiple sclerosis (MS) in immunological markers, hi...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608093978

    authors: Okamoto T,Ogawa M,Lin Y,Murata M,Miyake S,Yamamura T

    更新日期:2008-07-01 00:00:00

  • Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.

    abstract::Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286420909973

    authors: Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

    更新日期:2020-06-03 00:00:00

  • Erythropoietin: still on the neuroprotection road.

    abstract::Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611434926

    authors: Subirós N,Del Barco DG,Coro-Antich RM

    更新日期:2012-05-01 00:00:00

  • Capsaicinoids in the treatment of neuropathic pain: a review.

    abstract::The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285613501576

    authors: Peppin JF,Pappagallo M

    更新日期:2014-01-01 00:00:00

  • Current and emerging therapies in multiple sclerosis: a systematic review.

    abstract::Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285612450936

    authors: Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

    更新日期:2012-07-01 00:00:00

  • Natural toxins implicated in the development of Parkinson's disease.

    abstract::Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611413004

    authors: Salama M,Arias-Carrión O

    更新日期:2011-11-01 00:00:00

  • Can inflammation be resolved in Alzheimer's disease?

    abstract::Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286418791107

    authors: Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

    更新日期:2018-08-09 00:00:00

  • Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

    abstract:Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286420918088

    authors: Gklinos P,Mitsikostas DD

    更新日期:2020-04-28 00:00:00

  • Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction.

    abstract:Background:Lennox-Gastaut syndrome (LGS) is a typical intractable form of epilepsy that most often occurs between the second and sixth year of life. This study aimed to evaluate the clinical efficacy and safety of ketogenic diet therapies (DTs) for LGS with mitochondrial dysfunction. Methods:This was a retrospective s...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756286419897813

    authors: Na JH,Kim HD,Lee YM

    更新日期:2020-02-06 00:00:00

  • Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience.

    abstract::Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286419873518

    authors: Steinhoff BJ,Staack AM

    更新日期:2019-09-09 00:00:00

  • Efficacy and safety of laquinimod in multiple sclerosis: current status.

    abstract::Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613499424

    authors: Haggiag S,Ruggieri S,Gasperini C

    更新日期:2013-11-01 00:00:00

  • Vascular medicine and thrombectomy in stroke.

    abstract::The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285617742082

    authors: Fischer S,Weber W

    更新日期:2017-11-22 00:00:00

  • Advances in spinal muscular atrophy therapeutics.

    abstract::Spinal muscular atrophy (SMA) is a progressive, recessively inherited neuromuscular disease, characterized by the degeneration of lower motor neurons in the spinal cord and brainstem, which leads to weakness and muscle atrophy. SMA currently represents the most common genetic cause of infant death. SMA is caused by th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756285618754501

    authors: Parente V,Corti S

    更新日期:2018-02-05 00:00:00

  • Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies.

    abstract:OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an in...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285611415309

    authors: Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

    更新日期:2011-09-01 00:00:00

  • Paradoxical association of symptomatic cerebral edema with local hypoperfusion caused by the 'watershed shift' after revascularization surgery for adult moyamoya disease: a case report.

    abstract::Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

    journal_title:Therapeutic advances in neurological disorders

    pub_type:

    doi:10.1177/1756286419878343

    authors: Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

    更新日期:2019-09-25 00:00:00

  • Neutralizing antibodies against interferon-Beta.

    abstract::The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285608095144

    authors: Sorensen PS

    更新日期:2008-09-01 00:00:00

  • Advances in imaging of brain abnormalities in neuromuscular disease.

    abstract::Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Schol...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审

    doi:10.1177/1756286419845567

    authors: Angelini C,Pinzan E

    更新日期:2019-05-06 00:00:00

  • Diagnosis and treatment of impulse control disorders in patients with movement disorders.

    abstract::Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章

    doi:10.1177/1756285613476127

    authors: Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

    更新日期:2013-05-01 00:00:00